tiprankstipranks
Advertisement
Advertisement

NBIX Stock Latest News

Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
RatingsMyles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
23h ago
NBIX
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
1d ago
KNX
SHW
Neurocrine reinstated with a Buy at Goldman Sachs
PremiumThe Fly
Neurocrine reinstated with a Buy at Goldman Sachs
2d ago
NBIX
Neurocrine price target raised to $183 from $180 at RBC Capital
PremiumThe Fly
Neurocrine price target raised to $183 from $180 at RBC Capital
5d ago
NBIX
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
PremiumCompany Announcements
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
6d ago
8K
NBIX
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
PremiumThe FlyNeurocrine initiated with Outperform at Bernstein on long runway of key drugs
13d ago
NBIX
Neurocrine initiated with an Outperform at Bernstein
Premium
The Fly
Neurocrine initiated with an Outperform at Bernstein
13d ago
NBIX
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
Premium
Company Announcements
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
15d ago
NBIX
Neurocrine announces new data from a clinician survey in Ingrezza
PremiumThe Fly
Neurocrine announces new data from a clinician survey in Ingrezza
16d ago
NBIX
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
PremiumCompany Announcements
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
16d ago
8K
NBIX
Neurocrine completes acquisition of Soleno Therapeutics
PremiumThe Fly
Neurocrine completes acquisition of Soleno Therapeutics
16d ago
NBIX
SLNO
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
PremiumThe Fly
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
19d ago
AARD
NBIX
Neurocrine price target raised to $185 from $177 at JPMorgan
PremiumThe FlyNeurocrine price target raised to $185 from $177 at JPMorgan
26d ago
NBIX
Neurocrine price target raised to $155 from $140 at Truist
Premium
The Fly
Neurocrine price target raised to $155 from $140 at Truist
27d ago
NBIX
Neurocrine price target raised to $155 from $150 at Deutsche Bank
Premium
The Fly
Neurocrine price target raised to $155 from $150 at Deutsche Bank
27d ago
NBIX
Neurocrine treatment of Friedreich ataxia granted orphan designation
PremiumThe Fly
Neurocrine treatment of Friedreich ataxia granted orphan designation
27d ago
NBIX
Neurocrine price target raised to $246 from $242 at Citi
PremiumThe Fly
Neurocrine price target raised to $246 from $242 at Citi
27d ago
NBIX
Neurocrine price target raised to $207 from $190 at Piper Sandler
PremiumThe Fly
Neurocrine price target raised to $207 from $190 at Piper Sandler
28d ago
NBIX
SLNO
Neurocrine price target raised to $191 from $185 at Morgan Stanley
PremiumThe Fly
Neurocrine price target raised to $191 from $185 at Morgan Stanley
28d ago
NBIX
Neurocrine price target raised to $230 from $220 at Oppenheimer
PremiumThe FlyNeurocrine price target raised to $230 from $220 at Oppenheimer
28d ago
NBIX
Neurocrine price target raised to $155 from $140 at Truist
Premium
The Fly
Neurocrine price target raised to $155 from $140 at Truist
28d ago
NBIX
Evan Seigerman Maintains Hold on Neurocrine as Strong Commercial Execution Drives Price Target Increase to $144 Amid Strategic Uncertainty
Premium
Ratings
Evan Seigerman Maintains Hold on Neurocrine as Strong Commercial Execution Drives Price Target Increase to $144 Amid Strategic Uncertainty
28d ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >